Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Clinical trial NCT01091831 · COMPLETED

Trial details

NCT number: NCT01091831
Sponsor: Fondazione EMN Italy Onlus
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2009-07-01
Primary completion: 2021-09-01
Enrollment: 389

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.